Clin2
NCT07084831Possibly a fitNot yet recruiting

Study of Xanomeline/Trospium for memory in schizophrenia

Schizophrenia; PsychosisCognitive Impairment

Part of Mental health clinical trials.

This trial tests if a new treatment, xanomeline/trospium (XT), can help improve thinking and memory problems in adults with schizophrenia. You would take XT as a tablet alongside your current medication for up to 52 weeks.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
171 people
Ages
18 years to 55 years
Study type
Interventional

Who can take part

  • You are between 18 and 55 years old.
  • You have been diagnosed with schizophrenia and take a stable dose of an oral antipsychotic medication for at least 4 weeks.
  • You experience some cognitive difficulties (thinking, memory, or attention) that affect your daily life.
  • You are not currently suicidal, do not have severe depression or mania, and do not have severe substance or alcohol use disorder.
  • You have no major medical problems that would make the study unsafe, such as severe kidney, liver, or heart conditions.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06923891Not yet recruiting· Phase 4
Testing a new pill for early schizophrenia

This trial tests a new combination pill (xanomeline/trospium) for people who started treatment for schizophrenia in the last 5 years, to see if it helps better than their current medicine. You would stop your current antipsychotic and switch to this study drug under close doctor supervision.

Richmond, Texas
NCT06924255Not yet recruiting· Phase 4
Switching antipsychotics to xanomeline/trospium for schizophrenia

This study tests how well people with schizophrenia can switch from their current antipsychotic medication to a new combination drug, xanomeline/trospium, either quickly or slowly over 8 weeks. It may be an option if your current medication causes side effects or is not working well enough.

Bellflower, California
NCT07101094Recruiting
Study on satisfaction with a new schizophrenia treatment

This study tracks how satisfied people with schizophrenia are with a new combination medicine called xanomeline and trospium chloride (XT). It aims to understand real-world experiences and benefits of this treatment.

Costa Mesa, California
NCT07686263Not yet recruiting· Phase 3
Testing a new drug to prevent schizophrenia relapse

This trial tests whether a new oral medication, KarXT, can help prevent a return of schizophrenia symptoms in people who have been stable on treatment. If you've had a hospital stay in the past year and still have some symptoms, you may be able to join.

Bentonville, Arkansas
NCT07221877Recruiting· Phase 4
Study of KarXT for urological safety in schizophrenia

This study tests a new medicine (KarXT) for schizophrenia, focusing on how it affects urological (bladder and urinary) safety. You'll stop your current antipsychotic and take the study drug to see if it works well and is safe for your urinary system.

Little Rock, Arkansas
NCT07191483Recruiting· Phase 2
Study of KYN-5356 for cognitive problems in schizophrenia

This trial tests an investigational drug, KYN-5356, to see if it can improve thinking and memory problems in adults with schizophrenia. You may join if your schizophrenia is stable and you take only one antipsychotic medication.

Little Rock, Arkansas

Hear when a new Schizophrenia; Psychosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.